Abstract:Patients with non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations initially respond to small molecule inhibitors of the EGFR tyrosine kinase such as gefitinib and erlotinib. However, secondary mutations in the kinase domain lead to acquired resistance to these inhibitors and limited clinical efficacy, with the EGFR T790M mutation being the most common mechanism of acquired resistance in more than half the patients that experience disease progression. CK-101 (also known as RX518) is a novel, irreversible, orally administered EGFR kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) EGFR. WT EGFR inhibition is believed to drive the commonly observed side effects of skin rash and diarrhea. The 50% inhibitory concentrations (IC50s) of CK-101 and 2 reference compounds, afatinib and AZD-9291, were determined in cell proliferation assays in human cancer cell lines in vitro after incubation for 72 hours. Xenograft studies were conducted in BALB/c nude mice or SCID/Beige mice using once daily oral administration of CK-101 or afatinib for 14 or 21 days. CK-101 selectively inhibited cell proliferation of cell lines expressing both the activating (e.g. HCC827, IC50 0.5 µM; i.e., CK-101 was over 100 fold less potent against A431 than against NCI-H1975). Single agent CK-101 significantly inhibited tumor growth in EGFR-mutated NSCLC tumor xenograft models, with no activity in a WT EGFR tumor xenograft model. In a xenograft study of PC-9 cells (exon 19 deletion) in SCID/Beige mice, CK-101 inhibited tumor growth by up to 90% (p Citation Format: Xiangping Qian, Yong-Liang Zhu, Edward Cullen, Robert M. Niecestro, James F. Oliviero. CK-101 (RX518), a mutant-selective inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2078. doi:10.1158/1538-7445.AM2017-2078

Supplementary Figure 5 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 1 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 6 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Discovery of 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988), A Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Supplementary Figure 1 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Supplementary Figure 3 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Supplementary Figure 5 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Abstract 2078: CK-101 (RX518), a Mutant-Selective Inhibitor of EGFR That Overcomes T790M-mediated Resistance in NSCLC

Supplementary Table 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 6 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Structural Basis of Mutant-Selectivity and Drug-Resistance Related to CO-1686.

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Supplementary Table 1 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform